ADRIATIC Study Shows Benefit of Consolidation Durvalumab in LS-SCLC

Missak Haigentz, MD, professor of medicine at Rutgers Robert Wood Johnson Medical School, chief of Thoracic and Head and Neck Medical Oncology at the Rutgers Cancer Institute, discusses the impact of the impressive results seen in the ADRIATIC study (NCT03703297) with the administration of durvalumab (Imfinzi) as consolidation treatment after concurrent chemoradiation for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC).The findings from the first planned interim analysis of the phase 3 ADRIATIC study were shared during a press briefing at the 2024 ASCO Annual Meeting and showed there to be significantly improved survival vs placebo in this patient population.

At a median follow-up of 37.2 months (range, 0.1-60.9), the median overall survival was 55.9 months (95% CI, 37.3-not evaluable) with durvalumab (n = 264) compared with 33.4 months (95% CI, 25.5-39.9) with placebo (n = 266). This translated to a 27% reduction in the risk of death (HR, 0.73; 95% CI, 0.57-0.93; P = .0104).

Transcription:

0:09 | ADRIATIC is a phase 3, global, randomized, placebo controlled study of consolidative cancer immunotherapy following chemoradiotherapy for patients with limited-stage small cell lung cancer. This is a patient population for whom immunotherapy has not previously had an impact, a proven impact. And so this study really demonstrated for the first time the role of durvalumab in particular, as a consolidative therapy for this unique group of patients by improving overall survival.

0:54 | It's only the beginning. Really, the impressive results of ADRIATIC demonstrated that the overall survival was able to demonstrate reduction in risk of mortality by 27%. There were 10% gains in 2-year and 3-year overall survival that coupled with progression-free survival. However, really, at 2 years, even with this new therapy, more than 50% of patients had already had disease progression at 2 years. Here we are really heralding this advance. This is only the beginning of being able to study novel immunotherapies and combination immunotherapies. The ADRIATIC still has not read out its combination arm of durvalumab plus tremelimumab [Imjudo], and there are a whole number of other investigational studies that are seeking to improve on this.